Systematic Review of the Relation Between Intestinal Microbiota and Toll-Like Receptors in the Metabolic Syndrome: What Do We Know So Far?

GE Portuguese Journal of Gastroenterology

Volumn 22, Issue 6, 2015, Pages 240-258

  Portela Cidade, José Pedro ^a   Borges Canha, Marta ^a   Leite Moreira, Adelino Ferreira ^a   Pimentel Nunes, Pedro ^a,b  

^a University of Porto   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

Immunity, innate; Intestinal mucosa; Metabolic syndrome X; Microbiota; Toll Like receptors

Indexed keywords

EID: 84983132739     PISSN: 23414545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpge.2015.06.001     Document Type: Short Survey

References (47)

1. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014, 2014:943162.
2. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroenterol 2010, 44:S16-S18.
3. Mehal W.Z. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10:637-644.
4. Jialal I., Kaur H., Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab 2014, 99:39-48.
5. Jin C., Henao-Mejia J., Flavell R.A. Innate immune receptors: key regulators of metabolic disease progression. Cell Metab 2013, 17:873-882.
6. Parekh P.J., Arusi E., Vinik A.I., Johnson D.A. The role and influence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome. Front Endocrinol (Lausanne) 2014, 5:47.
7. Caricilli A.M., Picardi P.K., de Abreu L.L., Ueno M., Prada P.O., Ropelle E.R., et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol 2011, 9:e1001212.
8. Wiest R., Lawson M., Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014, 60:197-209.
9. Frasinariu O.E., Ceccarelli S., Alisi A., Moraru E., Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013, 45:543-551.
10. Seki E., Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012, 590:447-458.
11. Chassaing B., Etienne-Mesmin L., Gewirtz A.T. Microbiota-liver axis in hepatic disease. Hepatology 2014, 59:328-339.
12. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
13. Jialal I., Huet B.A., Kaur H., Chien A., Devaraj S. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012, 35:900-904.
14. Cuda C., Badawi A., Karmali M., El-Sohemy A. Polymorphisms in Toll-like receptor 4 are associated with factors of the metabolic syndrome and modify the association between dietary saturated fat and fasting high-density lipoprotein cholesterol. Metabolism 2011, 60:1131-1135.
15. Steinhardt A.P., Aranguren F., Tellechea M.L., Gómez Rosso L.A., Brites F.D., Martínez-Larrad M.T., et al. A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation. Metabolism 2010, 59:711-717.
16. Penas-Steinhardt A., Barcos L.S., Belforte F.S., de Sereday M., Vilariño J., Gonzalez C.D., et al. Functional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweight. PLoS ONE 2012, 7:e50992.
17. Belforte F.S., Coluccio Leskow F., Poskus E., Penas Steinhardt A. Toll-like receptor 4 D299G polymorphism in metabolic disorders: a meta-analysis. Mol Biol Rep 2013, 40:3015-3020.
18. Ehses J.A., Meier D.T., Wueest S., Rytka J., Boller S., Wielinga P.Y., et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010, 53:1795-1806.
19. Kuo L.H., Tsai P.J., Jiang M.J., Chuang Y.L., Yu L., Lai K.T., et al. Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse. Diabetologia 2011, 54:168-179.
20. Figueroa L., Xiong Y., Song C., Piao W., Vogel S.N., Medvedev A.E. The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J Immunol 2012, 188:4506-4515.
21. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
22. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
23. Backhed F., Ding H., Wang T., Hooper L.V., Koh G.Y., Nagy A., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004, 101:15718-15723.
24. Backhed F., Manchester J.K., Semenkovich C.F., Gordon J.I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007, 104:979-984.
25. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
26. Remely M., Aumueller E., Jahn D., Hippe B., Brath H., Haslberger A.G. Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 2014, 5:33-43.
27. Zhang C., Zhang M., Wang S., Han R., Cao Y., Hua W., et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J 2010, 4:232-241.
28. Ubeda C., Lipuma L., Gobourne A., Viale A., Leiner I., Equinda M., et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 2012, 209:1445-1456.
29. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
30. Kellermayer R., Dowd S.E., Harris R.A., Balasa A., Schaible T.D., Wolcott R.D., et al. Colonic mucosal DNA methylation, immune response, and microbiome patterns in Toll-like receptor 2-knockout mice. FASEB J. 2011, 25:1449-1460.
31. Wang J., Tang H., Zhang C., Zhao Y., Derrien M., Rocher E., et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J 2015, 9:1-15.
32. Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916. e917.
33. Leber B., Tripolt N.J., Blattl D., Eder M., Wascher T.C., Pieber T.R., et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur J Clin Nutr 2012, 66:1110-1115.
34. Sawada K., Ohtake T., Hasebe T., Abe M., Tanaka H., Ikuta K., et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice. Hepatol Res 2014, 44:920-934.
35. Ye D., Li F.Y., Lam K.S., Li H., Jia W., Wang Y. Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 2012, 61:1058-1067.
36. Rivera C.A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007, 47:571-579.
37. Csak T., Velayudham A., Hritz I., Petrasek J., Levin I., Lippai D., et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2011, 300:G433-G441.
38. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
39. Liang S., Webb T., Li Z. Probiotic antigens stimulate hepatic natural killer T cells. Immunology 2014, 141:203-210.
40. Xie Y.R., Liu S.L., Liu X., Luo Z.B., Zhu B., Li Z.F., et al. Intestinal microbiota and innate immunity-related gene alteration in cirrhotic rats with liver transplantation. Transplant Proc 2011, 43:3973-3979.
41. Henao-Mejia J., Elinav E., Thaiss C.A., Flavell R.A. The intestinal microbiota in chronic liver disease. Adv Immunol 2013, 117:73-97.
42. Sommer P., Sweeney G. Functional and mechanistic integration of infection and the metabolic syndrome. Korean Diabetes J 2010, 34:71-76.
43. Burcelin R., Garidou L., Pomie C. Immuno-microbiota cross and talk: the new paradigm of metabolic diseases. Semin Immunol 2012, 24:67-74.
44. Moschen A.R., Kaser S., Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab 2013, 24:537-545.
45. Duseja A., Chawla Y.K. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis 2014, 18:59-71.
46. Manco M., Putignani L., Bottazzo G.F. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010, 31:817-844.
47. Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014, 20:7381-7391.